Devita, Hellman, and Rosenberg's Cancer

LWBK1006-11 LWW-Govindan-Review November 24, 2011 11:21

CHAPTER 11 SYSTEMIC

THERAPY FOR CANCER

SARA K. BUTLER•LEIGH M. BOEHMER

DIRECTIONS Each of the numbered items below is followed by lettered answers. Select the

ONE lettered answer that is BEST in each case unless instructed otherwise.

QUESTIONS

Question 11.1. Which of the following patients would be the most likely to have the best

response from treatment with 5-FU?

A. A patient who is homozygous for 3R/3R triple repeat polymorphism

resulting in decreased thymidylate synthase (TS) levels

B. A patient who is homozygous for 2R/2R double repeat polymorphism

resulting in decreased TS levels

C. A patient who is homozygous for 3R/3R triple repeat polymorphism

resulting in increased TS levels

D. A patient who is homozygous for 2R/2R double repeat polymorphism

resulting in increased TS levels

Question 11.2. Which of the following scenarios best identifies a prognostic marker?

A. UGT1A1*28 testing in the setting of colon cancer

B. Dihydropyrimidine dehydrogenase (DPD) deficiency in the setting of

head and neck cancer induction chemotherapy

C. Deficiency in MMR protein expression (DNA mismatch repair gene)

in colon cancer

D. KRAS mutation testing in the setting of colon cancer

Question 11.3. Which of the following patients would be the most appropriate candidate

for high-dose methotrexate at standard doses?

A. A patient with an elevated bilirubin at 2.1 mg/dL

B. A patient with a moderate size left pleural effusion

C. A patient currently receiving amoxicillin for a dental abscess

D. A 63-year-old patient with a serum creatinine of 2.3 mg/dL

Corresponding Chapters inCancer: Principles & Practice of Oncology,Ninth Edition: 32 (Pharmacokinetics and

Pharmacodynamics), 33 (Pharmacogenomics), 34 (Alkylating Agents), 35 (Platinum Analogs), 36 (Antimetabolites),

37 (Topoisomerase-Interacting Agents), 38 (Antimicrotubule Agents), 39 (Targeted Therapy with Small Molecule

Kinase Inhibitors), 40 (Histone Deacetylase Inhibitors and Demethylating Agents), 41 (Proteosome Inhibitors),

42 (Poly(ADP-Ribose) Polymerase Inhibitors), 43 (Miscellaneous Chemotherapeutic Agents), 44 (Interferons),

45 (Interleukin Therapy), 46 (Antisense Agents), 47 (Antiangiogenesis Agents), 48 (Monoclonal Antibodies),

and 49 (Endocrine Manipulation).

123